Why we are reviewing these two together
On February 20, 2026, the FDA's Center for Drug Evaluation and Research issued a coordinated wave of warning letters to telehealth companies marketing compounded semaglutide and tirzepatide. SkinnyRx (operated by Lean Rx, Inc.) and 24hrDoc were both on the list. Both letters cite substantially the same categories of violation as the letters sent to MEDVi, Strut Health, and Newman Clinic the same day.
Rather than writing two separate short reviews of companies we do not recommend, we have combined them here into a single review that walks through the specific regulatory situation, what patients enrolled with either provider should know, and what we recommend instead.
Neither company is a standout villain. Both are examples of a pattern the FDA has now challenged across the industry: marketing compounded drugs in ways that implied FDA approval and using product labels that misrepresented who actually compounded the medication.
This review contains affiliate links to alternative providers we do recommend. We have no financial relationship with SkinnyRx or 24hrDoc. Compounded medications are not FDA-approved as finished products.
SkinnyRx and the February 20, 2026 warning letter
SkinnyRx is a direct-to-consumer telehealth brand operated by Lean Rx, Inc. The company's warning letter is one of the three that industry attorneys (publishing on the Little Health Law Blog) have called "representative examples of the FDA's enforcement focus," alongside Strut Health and Newman Clinic. All three were issued the same day by the Acting Director of the Office of Compounding Quality and Compliance within CDER.
The violations cited in the SkinnyRx warning letter fall into the same two categories seen across the enforcement wave:
Misbranding through labeling
The FDA found that SkinnyRx's website depicted compounded drug product labels bearing the "SkinnyRx" name, suggesting SkinnyRx was the actual compounder when in fact the company is not a licensed compounding pharmacy. Under federal labeling regulations, placing a name on a drug label without qualification represents that the named entity is the sole manufacturer.
Misbranding through implied FDA approval
The letter also identified marketing language that implied the compounded products had been reviewed or approved by the FDA. Compounded medications are explicitly not FDA-approved as finished products, and any marketing that suggests otherwise is considered false or misleading under the Federal Food, Drug, and Cosmetic Act.
As with all recipients, SkinnyRx had 15 working days to respond in writing with specific corrective actions. The FDA publicly warned that failure to adequately address violations could result in legal action including seizure and injunction.
24hrDoc and warning letter #717984
24hrDoc is a telehealth brand marketing rapid-access prescription services including compounded GLP-1 medications. The company received warning letter #717984 on February 20, 2026, part of the same enforcement wave. The letter cites the same fundamental misbranding violations — misleading labeling suggesting 24hrDoc was the compounder, and marketing language implying FDA approval of compounded products.
The 24hrDoc brand emphasizes speed in its marketing — fast intake, fast prescription, fast shipping. That velocity may be a legitimate service distinction, but it is also the kind of messaging that tends to blur the distinction between FDA-approved medications and compounded alternatives. The FDA's concern in these letters is precisely that telehealth companies have been presenting compounded products in ways that do not adequately communicate the regulatory and quality differences from FDA-approved products.
The February 20, 2026 warning letter wave included SkinnyRx, 24hrDoc, MEDVi, Strut Health, Newman Clinic, and others. In March 2026, the FDA issued more than 30 additional warning letters to telehealth companies for similar violations. According to STAT News, at least 30% of the warned companies shared clinical ties to just four nationwide medical groups — suggesting a relatively concentrated backend that was being marketed under many different consumer-facing brands.
The pattern across both letters
Reading the SkinnyRx and 24hrDoc letters side-by-side with MEDVi's and Strut's reveals a consistent FDA enforcement posture. The agency is not arguing that compounded GLP-1 medications are categorically unsafe or illegal — compounding is authorized under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The FDA is instead enforcing the distinction between FDA-approved products and compounded preparations, which has clinical and legal meaning that telehealth marketing has often blurred.
The violations the FDA cited across this enforcement wave are not cosmetic. The specific misrepresentations — who compounded the drug, whether the drug was FDA-evaluated — go to the heart of what a patient is being sold.
For a patient, this is not an academic question. If you enrolled in SkinnyRx or 24hrDoc believing (based on the website's presentation) that you were getting an FDA-approved medication, and you were actually getting a compounded preparation from a third-party pharmacy, you received a materially different product from what you expected. Your clinical outcomes, your safety profile, and your insurance situation all differ accordingly.
What happens next for enrolled patients
A warning letter does not suspend a company's operations or invalidate individual prescriptions. Your medication, if filled by a licensed pharmacy, remains a valid prescription. But it does create uncertainty about:
- Program continuity. If the FDA escalates to injunction or seizure, the company's ability to operate could be affected.
- Documentation. If you ever need to produce records of your medication history — for a new prescriber, for insurance, for a future pharmacy — documentation quality from an embattled provider may be less reliable.
- Clinical follow-up. If a company is navigating regulatory issues, its attention and operational capacity may be focused there rather than on patient care quality.
What we recommend instead
For both existing SkinnyRx/24hrDoc patients considering switching and for new enrollees researching these providers, we recommend one of the following paths:
Sesame Care — FDA-approved medications, clean paper trail
Sesame Care is a Novo Nordisk Recognized Care Provider. Clinicians on the platform can prescribe FDA-approved brand-name Wegovy pill, Rybelsus, or Foundayo — not compounded alternatives. Starting fresh with an FDA-approved path avoids the documentation and regulatory uncertainty of a compounded provider under enforcement action.
SHED — compounded, without the warning letter
If you specifically want a compounded GLP-1 program (typically for cost reasons), SHED did not receive a warning letter in the 2026 enforcement waves. LegitScript-certified, widest oral format variety (tablet, ODT, lozenge), and transparent about which 503A compounding pharmacy fills each prescription. Compounded medications are not FDA-approved.
Bottom line
We do not recommend SkinnyRx or 24hrDoc for new enrollments in April 2026. Both companies have active FDA warning letters identifying misbranding violations that go to the core of how patients understand what they are buying. There are safer, better-documented alternatives at comparable or lower cost.
For existing patients of either provider who are satisfied with their clinical results, the conservative course is to maintain current treatment while monitoring whether the FDA situation progresses to a closeout (indicating the company has resolved the violations) or to further enforcement. If your provider's warning letter situation concerns you, a switch to Sesame Care (FDA-approved path) or SHED (cleaner compounded path) is straightforward.
Is my SkinnyRx or 24hrDoc prescription still valid?
Yes. A warning letter is a communication to the company, not a revocation of individual prescriptions. Your medication, if filled by a licensed pharmacy, remains legal. The concerns are about marketing and labeling practices, not about the clinical validity of prescriptions already written.
Did either company respond to the FDA?
Both were required to respond within 15 working days. Individual responses are generally not made public unless the FDA subsequently issues a "close-out letter" (indicating resolution) or escalates to further enforcement. As of this writing, no public close-out has been issued for either.
How do I cancel my membership?
Check the terms of service on the specific provider's website for cancellation procedures. Both companies handle cancellation through their patient portals or support channels. Do so before your next billing cycle to avoid additional charges.
Can I transfer my prescription to another provider?
Compounded prescriptions are generally not transferable between compounding pharmacies in the same way that retail pharmacy prescriptions are. You would typically start fresh with a new provider — a new intake, a new clinician consultation, a new prescription. Sesame Care and SHED both have straightforward intake processes.
Are other compounded GLP-1 providers safe?
The regulatory situation varies provider by provider. Some companies received warning letters; others did not. Even within the group that did not receive letters, regulatory standing is not binary — it reflects specific marketing and labeling practices at specific points in time. Our review of SHED covers what a cleaner compounded operation looks like.